Home › SEC Filings › Current Report (8-K)
Current Report (8-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MYPS | 8-K | bearish | 6/10 | PLAYSTUDIOS reported Q2 2026 revenue of $55.0M, down 7.3% YoY from $59.3M, and a net loss of $13.3M (loss per share -$0. | Aug 11, 2026 |
| ZARE | 8-K | neutral | 3/10 | Ares Real Estate Income Trust Inc. announced a distribution increase from $0.03450 per share to $0.03583 per share for A | Aug 11, 2026 |
| AME | 8-K | neutral | 2/10 | AMETEK increased its commercial paper program capacity from $2.3 billion to $3.5 billion, maintaining the same $3.5 bill | Aug 11, 2026 |
| BHM | 8-K | neutral | 4/10 | Bluerock Homes Trust completed the sale of 26 single-family residential units from its Golden Pacific joint venture port | Aug 11, 2026 |
| FSBW | 8-K | neutral | 2/10 | FS Bancorp filed an 8-K to furnish investor materials in connection with management's virtual participation in the D.A. | Aug 11, 2026 |
| LMED | 8-K | neutral | 1/10 | LataMed AI Corp. filed an 8-K to announce that its common stock resumed trading under its permanent ticker LMED on Augus | Aug 11, 2026 |
| CCFN | 8-K | neutral | 2/10 | Muncy Columbia Financial Corporation (CCFN) declared a regular quarterly cash dividend of $0.155 per share for Q3 2026, | Aug 11, 2026 |
| EMYB | 8-K | neutral | 2/10 | Embassy Bancorp filed an 8-K reporting the passing of Director John G. Englesson on August 7, 2026. Mr. Englesson had se | Aug 11, 2026 |
| MBOT | 8-K | bullish | 5/10 | Microbot Medical filed its Q2 2026 10-Q and highlighted revenue growth of more than 100% sequentially, driven by the Ful | Aug 11, 2026 |
| IVZ | 8-K | mixed | 5/10 | Invesco reported preliminary July 2026 AUM of $2,447.1 billion, down 0.9% month-over-month, driven by unfavorable market | Aug 11, 2026 |
| BIXT | 8-K | bullish | 5/10 | Bioxytran reported encouraging clinical observations from the first CIDP patient treated with PLICID, a galectin antagon | Aug 11, 2026 |
| BTAI | 8-K | bearish | 7/10 | BioXcel Therapeutics entered its Twelfth Amendment to the Oaktree credit agreement, extending the deadline to August 21, | Aug 11, 2026 |
| HBIO | 8-K | mixed | 5/10 | Harvard Bioscience filed an 8-K with an investor presentation providing updated FY26 guidance: revenue growth raised to | Aug 11, 2026 |
| XXI | 8-K | neutral | 4/10 | CEO Raphael Zagury issued a shareholder letter outlining a five-priority strategy to transform Twenty One from a Bitcoin | Aug 11, 2026 |
| MIDD | 8-K | bullish | 7/10 | Middleby Corp reported Q2 2026 adjusted EPS of $2.35, a 12.4% beat vs the $2.09 consensus, and net sales of $875.5M (con | Aug 11, 2026 |
| REFI | 8-K | bearish | 6/10 | Chicago Atlantic Real Estate Finance (REFI) reported Q2 2026 Distributable Earnings per diluted share of $0.43, a 4.4% m | Aug 11, 2026 |
| UPB | 8-K | neutral | 4/10 | Upstream Bio reported Q2 2026 financial results with a net loss of $39.7M, roughly in line with the $40.0M loss in Q2 20 | Aug 11, 2026 |
| MASS | 8-K | neutral | 5/10 | The company raised the low end of its full-year revenue guidance to $68M-$70M (from $67M-$70M), implying 21%-25% YoY gro | Aug 11, 2026 |
| VSTS | 8-K | mixed | 6/10 | Vestis reported fiscal Q3 2026 revenue of $661.7M (-1.8% YoY), missing consensus of $669.0M, but adjusted diluted EPS of | Aug 11, 2026 |
| CW | 8-K | neutral | 4/10 | Curtiss-Wright announced a $100 million expansion of its 2026 share repurchase program via a 10b5-1 trading plan, bringi | Aug 11, 2026 |
| IMUX | 8-K | neutral | 5/10 | Immunic reported Q2 2026 net loss of $34.1M ($0.80/share), roughly matching the Street consensus of -$1.24 (narrower los | Aug 11, 2026 |
| DPC | 8-K | bullish | 7/10 | DPC Holdings reported Q2 2026 revenue of $269M (+34% YoY) and adjusted EPS of $0.05, beating consensus estimates of $0.0 | Aug 11, 2026 |
| XTNT | 8-K | bearish | 6/10 | Xtant Medical reported Q2 2026 revenue of $23.0M, a 35% YoY decline from $35.4M, and a net loss of $9.4M vs net income o | Aug 11, 2026 |
| BYND | 8-K | neutral | 4/10 | Beyond Meat announced a 1-for-30 reverse stock split and authorized share reduction, effective August 13, 2026, to regai | Aug 11, 2026 |
| CVRX | 8-K | bearish | 5/10 | CVRx terminated Chief Revenue Officer Robert John effective immediately, citing a 'revised commercial outlook' and need | Aug 11, 2026 |
| COAG | 8-K | bullish | 7/10 | Hemab Therapeutics reported Q2 2026 net loss of $24.2M ($0.80/share), wider than the $12.2M loss in Q2 2025 but in line | Aug 11, 2026 |
| CCCC | 8-K | neutral | 5/10 | C4 Therapeutics reported Q2 2026 revenue of $6.6M (up 2.7% YoY) and a net loss of $23.6M ($0.18 per share), beating the | Aug 11, 2026 |
| VREOF | 8-K | mixed | 6/10 | Vireo Growth reported Q2 2026 GAAP revenue of $209.3M (+335% YoY), massively beating the $167.4M consensus, but GAAP EPS | Aug 11, 2026 |
| CALC | 8-K | bearish | 6/10 | CalciMedica reported Q2 2026 financial results with a net loss of $7.7M ($0.45/share), wider than the $6.0M loss in Q2 2 | Aug 11, 2026 |
| SGC | 8-K | neutral | 4/10 | Superior Group of Companies refinanced its existing $200M senior secured credit facility with a new $200M facility ($125 | Aug 11, 2026 |